Skip to content

DEVLIES PHARMA

Active
Private limited companyfounded 2005active for 20 yearsMoeskroensesteenweg(Aal) 81, 8511 Kortrijk, BelgiumKBO/BCE: BE 0877.804.765
Summary

DEVLIES PHARMA has been active since 2005 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €149,857 and a net result of -€13,894. Equity remains stable across the filed financial years (±0.3% per year). Its solvency ranks better than 34% of 12,678 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.5% (very low).

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€675,641total assets 2025
Staff
0.8 FTE
Equity
€149,857
Loss
-€13,894
Turnover not published (abbreviated format)
Financial health
80 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.5%
Structure
2025 accounts 47 days early6 deeds in the Belgian Official Gazette
Why 80raises riskSector: Retail trade (NACE 47)lowers riskSize: 0.8 FTE, total assets €675,641Founded in 2005Figures for financial year 2025 (filed 15-12-2025)Show the evidence

Checked score

Score 2025
80 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 30% of its sector peers (NACE 47, micro)
Financial strength · tick = 2024
Weak
Solvency 47-1
equity 22.2% of total assets
Liquidity 31=
short-term debt 48.9% · cash 4.0%
Profitability 38-12
return on assets -2.1%
Bankruptcy probability, 12 months
0.5% Very low
0%0.5%1.5%4%10%≥ 25%

About 5 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,242 companies, NACE 47, micro)
Last 24 months 11-2024: 0.4% 12-2024: 0.4%● unchanged vs 11-2024 01-2025: 0.3%▼ -0.1 percentage points vs 12-2024lowest value 02-2025: 0.3%● unchanged vs 01-2025 03-2025: 0.3%● unchanged vs 02-2025 04-2025: 0.3%● unchanged vs 03-2025 05-2025: 0.3%● unchanged vs 04-2025 06-2025: 0.3%● unchanged vs 05-2025 07-2025: 0.3%● unchanged vs 06-2025 08-2025: 0.3%● unchanged vs 07-2025 09-2025: 0.3%● unchanged vs 08-2025 10-2025: 0.4%▲ +0.1 percentage points vs 09-2025 11-2025: 0.4%● unchanged vs 10-2025 12-2025: 0.4%● unchanged vs 11-2025 01-2026: 0.4%● unchanged vs 12-2025 02-2026: 0.4%● unchanged vs 01-2026 03-2026: 0.4%● unchanged vs 02-2026 04-2026: 0.4%● unchanged vs 03-2026 05-2026: 0.4%● unchanged vs 04-2026 06-2026: 0.4%● unchanged vs 05-2026 07-2026: 0.4%● unchanged vs 06-2026 08-2026: 0.4%● unchanged vs 07-2026 09-2026: 0.5%▲ +0.1 percentage points vs 08-2026 10-2026: 0.5%● unchanged vs 09-2026highest value
Credit of up to €11,000 on 30-day terms is acceptable
Liquidity tight (current ratio 1.01, compared with 0.96 in 2024, below the usual 1.5; short-term debt: 48.9% and cash: 4% of total assets), and 77.8% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 38% on solvency, 28% on liquidity, 29% on profitability and 28% on growth.

The bankruptcy probability was computed on 25-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · Sector: Retail trade (NACE 47)
KBO
lowers risk · Size: 0.8 FTE, total assets €675,641
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
lowers risk · Founded in 2005
Companies that have existed this long fail less often; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Figures for financial year 2025 (filed 15-12-2025)
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 15-12-2025, 47 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
47 days early
2024
32 days early
2023
44 days early
2022
32 days early
2021
41 days early
2020
31 days early
2019
46 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 39 days before the deadline; the sector median (NACE 47) for financial year 2024 is on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 21 December (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
30-06-2026 year end26-10-2026 today31-01-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · abbreviated…
  2. Weakest financial yearnet -€13,894
  3. Annual accounts filedfinancial year 2024 · abbreviated…

Financials · financial year 2025, abbreviated format

Equity
€149,857▼ 8.5%
2024 · €163,750
Total assets
€675,641▼ 5.8%
2024 · €717,552
Net result
-€13,894
2024 · €5,533
Working capital
€3,948
2024 · -€11,877
Trend over the years

2021 to 2025, 5 financial years 2019 to 2025, 7 financial years

The operating result falls in 2025; 2025 is 68% below 2024.

What the company sold each financial year and what was left of it. A loss stands below the zero line.

Operating result€8,816 2025 Net result-€13,894 2025

Use the arrow keys on the chart for the figures per year.

Sector: the middle half of NACE 47, Retail trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA), Staff (FTE).

Every figure with its change against the financial year before
favourable unfavourable
Line2019202020212022202320242025
Operating result€10,329-€10,279▼ 0.5%€12,129▲ 18.0%€8,410▼ 30.7%€11,698▲ 39.1%€27,838▲ 138%€8,816▼ 68.3%
Net result€19-€804below the sector's middle half▲ 43×€32below the sector's middle half▼ 96.0%€435below the sector's middle half▲ 14×€656below the sector's middle half▲ 50.5%€5,533within the sector's middle half▲ 744%-€13,894below the sector's middle half
Equity€156,290-€157,094within the sector's middle half▲ 0.5%€157,126within the sector's middle half=€157,562within the sector's middle half▲ 0.3%€158,217within the sector's middle half▲ 0.4%€163,750within the sector's middle half▲ 3.5%€149,857within the sector's middle half▼ 8.5%
Total assets€905,917-€880,766within the sector's middle half▼ 2.8%€827,133within the sector's middle half▼ 6.1%€779,599within the sector's middle half▼ 5.7%€760,706within the sector's middle half▼ 2.4%€717,552within the sector's middle half▼ 5.7%€675,641within the sector's middle half▼ 5.8%
Debt€749,627-€723,672▼ 3.5%€670,006▼ 7.4%€622,037▼ 7.2%€602,488▼ 3.1%€553,802▼ 8.1%€525,785▼ 5.1%
Working capital-€9,455--€52,916below the sector's middle half▼ 460%-€54,564below the sector's middle half▼ 3.1%-€42,707below the sector's middle half▲ 21.7%-€39,551below the sector's middle half▲ 7.4%-€11,877below the sector's middle half▲ 70.0%€3,948within the sector's middle half
Solvency17.3%-17.8%within the sector's middle half▲ 0.6pp19.0%within the sector's middle half▲ 1.2pp20.2%within the sector's middle half▲ 1.2pp20.8%within the sector's middle half▲ 0.6pp22.8%within the sector's middle half▲ 2.0pp22.2%within the sector's middle half▼ 0.6pp
Current ratio0.96-0.83below the sector's middle half▼ 0.130.83below the sector's middle half=0.87below the sector's middle half▲ 0.040.89below the sector's middle half▲ 0.020.96below the sector's middle half▲ 0.081.01within the sector's middle half▲ 0.05
Return on assets (ROA)0.0%-0.1%below the sector's middle half▲ 0.1pp0.0%below the sector's middle half▼ 0.1pp0.1%below the sector's middle half▲ 0.1pp0.1%below the sector's middle half=0.8%within the sector's middle half▲ 0.7pp-2.1%below the sector's middle half▼ 2.8pp
Staff (FTE)1.1below the sector's middle half0.8below the sector's middle half▼ 27.3%0.8below the sector's middle half=0.8below the sector's middle half=0.8below the sector's middle half=
above within below the middle half of NACE 47, Retail trade: a quarter of companies sit below it, a quarter above. Each year compared with accounts in the same format, and only where there are at least 30.
Turnover and EBIT margin not published: the abbreviated format does not require them.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €675,641
Fixed assets €341,409 ▼ 13.7%
Current assets €334,233 ▲ 3.8%
Equity and liabilities €675,641
Equity €149,857 ▼ 8.5%
Debt €525,785 ▼ 5.1%
Debt's share of the balance-sheet total rises from 77.2% to 77.8%. Equity and debt are lower.
Key figures and ratios
2025 value · change against 2024
EBITDA
€62,906▼
2024 · €88,259
Cash flow
€40,197▼
2024 · €65,954
Quick ratio
0.41▲
2024 · 0.39
Debt to equity
3.51▲
2024 · 3.38
ROE
-9.3%▼
2024 · 3.4%
Interest coverage
2.58▼
2024 · 3.60
Debt ≤ 1 year
€330,285▼
2024 · €333,829
Debt > 1 year
€195,500▼
2024 · €219,063
Income taxes
€0▼
2024 · €138
Staff costs
€61,055▲
2024 · €59,635
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Peer companies

Historical observation

Of the 2,450 companies that looked in July 2024 the way this one looks now, 1.5% went bankrupt within 24 months and 93.3% are still going.

  • Micro
  • 20 years or older
  • solvency 10 to 30%
  • a small loss
1.5% went bankrupt
5.1% stopped otherwise
93.3% still going

A further 0.2% stopped, but we cannot tell whether within those 24 months.

For this company itself Checked computes a bankruptcy probability of 0.5% over twelve months; the group does not contradict it.

How reliable is this rule?

Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,475 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.

The companies in ten equal groups, from lowest to highest expected share.
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74.5% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.

An observation about 2,450 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.

Annual accounts
Filed annual accounts As filed with the NBB · 2025 against 2024 · 53 lines
Balance sheet Code20242025
Assets
Total assets20/58€717,552€675,641▼
Fixed assets21/28€395,600€341,409▼
Tangible fixed assets22/27€395,500€341,409▼
Land and buildings22€353,072€330,642▼
Plant, machinery and equipment23€40,012€9,426▼
Furniture and vehicles24€2,416€1,341▼
Financial fixed assets28€100€0▼
Current assets29/58€321,953€334,233▲
Stocks and contracts in progress3€191,539€199,985▲
Stocks30/36€191,539€199,985▲
Amounts receivable within one year40/41€91,012€89,033▼
Trade receivables40€83,274€83,758▲
Other amounts receivable41€7,739€5,274▼
Current investments50/53€2,778€2,778=
Cash at bank and in hand54/58€21,104€26,833▲
Deferred charges and accrued income490/1€15,519€15,604▲
Equity and liabilities
Total equity and liabilities10/49€717,552€675,641▼
Equity10/15€163,750€149,857▼
Contributions10/11€180,000€180,000=
Reserves13€18,000€18,000=
Distributable reserves133€18,000€18,000=
Profit (loss) carried forward14-€34,250-€48,144▼
Amounts payable17/49€553,802€525,785▼
Amounts payable after more than one year17€219,063€195,500▼
Financial debts170/4€219,063€195,500▼
Amounts payable within one year42/48€333,829€330,285▼
Current portion of amounts payable after more than one year42€35,159€123,562▲
Financial debts43€140,000€75,000▼
Credit institutions430/8€140,000€75,000▼
Trade debts44€124,298€125,087▲
Suppliers440/4€124,298€125,087▲
Taxes, remuneration and social security45€6,988€5,751▼
Taxes450/3€1,624€3,260▲
Remuneration and social security454/9€5,364€2,491▼
Other amounts payable47/48€27,384€884▼
Accrued charges and deferred income492/3€910€0▼
Income statement Code20242025
Remuneration, social security and pensions62€59,635€61,055▲
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€60,421€54,091▼
Other operating charges640/8€3,304€2,970▼
Non-recurring operating charges66A€697€0▼
Gross operating margin9900€151,895€126,931▼
Operating profit (loss)9901€27,838€8,816▼
Financial income75/76B€2,359€1,711▼
Recurring financial income75€2,359€1,711▼
Financial charges65/66B€24,526€24,420▼
Recurring financial charges65€24,526€24,420▼
Profit (loss) for the period before taxes9903€5,671-€13,894▼
Income taxes67/77€138€0▼
Profit (loss) for the period9904€5,533-€13,894▼
Profit (loss) for the period to be appropriated9905€5,533-€13,894▼
Appropriation of the result
Profit (loss) to be appropriated9906-€34,250-€48,144▼
Profit (loss) brought forward from the previous period14P-€39,783-€34,250▲
Social balance sheet
Average headcount (FTE)90870.80.8=

The notes to these accounts (20 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Line2019202020212022202320242025Change
Remuneration, social security and pensions62---€52,008€57,084€59,635€61,055▲ 2.4%
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€62,138€66,001€64,926€61,738€58,537€60,421€54,091▼ 10.5%
Other operating charges640/8---€4,721€1,546€3,304€2,970▼ 10.1%
Non-recurring operating charges66A-----€697€0▼ 100%
Gross operating margin9900€126,495€117,339€130,448€126,878€128,864€151,895€126,931▼ 16.4%
Operating profit (loss)9901€10,329€10,279€12,129€8,410€11,698€27,838€8,816▼ 68.3%
Financial income75/76B---€3,443€2,792€2,359€1,711▼ 27.5%
Recurring financial income75€3,274€3,616€2,690€3,443€2,792€2,359€1,711▼ 27.5%
Financial charges65/66B---€11,364€13,772€24,526€24,420▼ 0.4%
Recurring financial charges65€13,519€13,034€14,719€11,364€13,772€24,526€24,420▼ 0.4%
Profit (loss) for the period before taxes9903€84€861€100€489€718€5,671-€13,894-
Income taxes67/77€65€56€68€54€62€138€0▼ 100.0%
Profit (loss) for the period9904€19€804€32€435€656€5,533-€13,894-
Profit (loss) for the period to be appropriated9905€19€804€32€435€656€5,533-€13,894-
Line2019202020212022202320242025Change
Assets
Total assets20/58€905,917€880,766€827,133€779,599€760,706€717,552€675,641▼ 5.8%
Fixed assets21/28€655,632€620,884€558,269€500,490€451,990€395,600€341,409▼ 13.7%
Tangible fixed assets22/27€655,532€620,784€558,169€500,390€451,890€395,500€341,409▼ 13.7%
Land and buildings22---€397,930€375,501€353,072€330,642▼ 6.4%
Plant, machinery and equipment23---€88,878€69,268€40,012€9,426▼ 76.4%
Furniture and vehicles24---€13,582€7,120€2,416€1,341▼ 44.5%
Leasing and similar rights25---€0----
Financial fixed assets28€100€100€100€100€100€100€0▼ 100%
Current assets29/58€250,286€259,882€268,864€279,109€308,716€321,953€334,233▲ 3.8%
Stocks and contracts in progress3€142,292€141,399€161,111€152,404€186,874€191,539€199,985▲ 4.4%
Stocks30/36---€152,404€186,874€191,539€199,985▲ 4.4%
Amounts receivable within one year40/41€55,620€77,822€66,078€69,980€82,269€91,012€89,033▼ 2.2%
Trade receivables40---€62,924€76,029€83,274€83,758▲ 0.6%
Other amounts receivable41---€7,056€6,240€7,739€5,274▼ 31.8%
Current investments50/53€2,778€2,778€2,778€2,778€2,778€2,778€2,778=
Cash at bank and in hand54/58€29,913€8,605€6,118€21,091€18,563€21,104€26,833▲ 27.1%
Deferred charges and accrued income490/1---€32,856€18,233€15,519€15,604▲ 0.5%
Equity and liabilities
Total equity and liabilities10/49€905,917€880,766€827,133€779,599€760,706€717,552€675,641▼ 5.8%
Equity10/15€156,290€157,094€157,126€157,562€158,217€163,750€149,857▼ 8.5%
Contributions10/11€180,000€0-€180,000€180,000€180,000€180,000=
Reserves13€18,000€18,000€18,000€18,000€18,000€18,000€18,000=
Non-distributable reserves130/1---€0----
Reserves not available under the articles1311---€0----
Distributable reserves133---€18,000€18,000€18,000€18,000=
Profit (loss) carried forward14-€41,710-€40,906-€40,874-€40,438-€39,783-€34,250-€48,144▼ 40.6%
Amounts payable17/49€749,627€723,672€670,006€622,037€602,488€553,802€525,785▼ 5.1%
Amounts payable after more than one year17€489,887€410,874€346,067€300,221€254,222€219,063€195,500▼ 10.8%
Financial debts170/4---€300,221€254,222€219,063€195,500▼ 10.8%
Amounts payable within one year42/48€259,740€312,798€323,428€321,816€348,267€333,829€330,285▼ 1.1%
Current portion of amounts payable after more than one year42---€45,846€46,000€35,159€123,562▲ 251%
Financial debts43---€140,000€140,000€140,000€75,000▼ 46.4%
Credit institutions430/8---€140,000€140,000€140,000€75,000▼ 46.4%
Trade debts44€59,007€102,719€89,664€92,473€121,511€124,298€125,087▲ 0.6%
Suppliers440/4---€92,473€121,511€124,298€125,087▲ 0.6%
Taxes, remuneration and social security45---€5,883€3,447€6,988€5,751▼ 17.7%
Taxes450/3---€2,048€1,032€1,624€3,260▲ 101%
Remuneration and social security454/9---€3,836€2,414€5,364€2,491▼ 53.6%
Other amounts payable47/48---€37,614€37,309€27,384€884▼ 96.8%
Accrued charges and deferred income492/3---€0-€910€0▼ 100%
Line2019202020212022202320242025Change
Profit (loss) for the period9904€19€804€32€435€656€5,533-€13,894-
+ Depreciation and write-downs630€62,138€66,001€64,926€61,738€58,537€60,421€54,091▼ 10.5%
Operating cash flow (approximation)€62,157€66,805€64,957€62,174€59,193€65,954€40,197▼ 39.1%
Investment in fixed assets (approximation)--€31,253-€2,310-€3,960-€10,037-€4,031€100-
Change in cash--€21,308-€2,487€14,973-€2,528€2,541€5,729▲ 125%

Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.

Download as CSV

Latest 10 of 19 filings with the National Bank
Financial year Type Filed Reference
30-06-2025 abbreviated format 15-12-2025 2025-00581323
30-06-2024 abbreviated format 30-12-2024 2024-00626513
30-06-2023 abbreviated format 18-12-2023 2023-00530416
30-06-2022 abbreviated format 30-12-2022 2022-20549279
30-06-2021 abbreviated format 21-12-2021 2021-80800395
30-06-2020 abbreviated format 31-12-2020 2020-77500412
30-06-2019 abbreviated format 16-12-2019 2019-76000549
30-06-2018 abbreviated format 24-01-2019 2019-02100534
30-06-2017 abbreviated format 31-01-2018 2018-03100314
30-06-2016 abbreviated format 26-12-2016 2016-71900400

Show all 19 filings

Similar companies · same sector, comparable size

Of the 5,204 active companies whose main activity is retail sale of pharmaceutical products (NACE 47730), figures are known for 3,892. 3,590 are within a factor 10 of this equity. These 5 are the closest to it. See the whole sector

Public contracts: No European public contracts awarded found since October 2016. Contracts below the EU thresholds are not in TED.

Directors

Directors
No directors read yet: 0 of 6 Gazette acts processed. See the directors and other office holders in the KBO →

Owners and capital

Owners

No owners or capital events in the accounts and acts we read.

History

On 9 December 2005, DEVLIES PHARMA was incorporated.1 Total assets went from €905,917 in 2019 to €675,641 in 2025 and headcount from 1.1 full-time equivalents in 2021 to 0.8 in 2025.2

  1. 1KBO register
  2. 2National Bank, annual accounts 2019, 2021 and 2025

Acts, filings and financial milestones

Next filing, financial year 2026, expected by 31-01-2027
2025
15-12
NBB filing Annual accounts filed
financial year 2025 · abbreviated format
30-06
Financial Weakest financial yearnet -€13,894
Net result drops to -€13,894, the lowest in the series.
2024
30-12
NBB filing Annual accounts filed
financial year 2024 · abbreviated format
30-06
Financial Highest result from 2019 to 2025net €5,533 ▲744%
Operating result €27,838, net result €5,533, both a record.
2023
18-12
NBB filing Annual accounts filed
financial year 2023 · abbreviated format
2022
30-12
NBB filing Annual accounts filed
financial year 2022 · abbreviated format
2021
21-12
NBB filing Annual accounts filed
financial year 2021 · abbreviated format
2020
31-12
NBB filing Annual accounts filed
financial year 2020 · abbreviated format
2019
16-12
NBB filing Annual accounts filed
financial year 2019 · abbreviated format
24-01
NBB filing Annual accounts filed
financial year 2018 · abbreviated format
2018
31-01
NBB filing Annual accounts filed
financial year 2017 · abbreviated format
2016
26-12
NBB filing Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 19 annual accounts filed, the latest 10 are here; all 19 are under Financials.
0 of 6 deeds read
About the unread acts

We know of 6 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.

Have them read with priority Sign in to place this company at the front of the reading queue.

Register details

Identification
Legal formPrivate limited company
Founded09-12-2005
Financial year end30-06
Abbreviation NL D PHARMA
Activities, NACEBEL 2025
47730Retail sale of pharmaceutical products
21209Manufacture of basic pharmaceutical products and pharmaceutical preparations
47741Retail sale of medical and orthopaedic goods, excluding prescription glasses and lenses
47750Retail sale of cosmetics and toilet articles
86910Medical imaging and medical laboratories
E-invoicing
Reachable via Peppol
Peppol ID 0208:0877804765
Also 9925:BE0877804765
Registered 29-12-2025

If you follow this company, Checked tells you the day it leaves the Peppol register.

Register as of 26 October 2026 · Peppol Directory

Scores and ratios are computed by Checked and are not a credit decision.

Environmental permits

1 application in Flanders since 2025 · 1 granted
Functiewijziging
Granted on 17-06-2025submitted 28-02-2025authority: Kortrijkproject 2025024769

Source: Omgevingsloket Vlaanderen. Flanders only: Brussels and Wallonia do not publish the applicant.

Sites & property

Location & real-estate footprint
Registered office, Kortrijk · 1 establishment unit since 2006
registered office establishment The establishment unit on the map
Ground area
1,099 m²
Building footprint
124 m²
Building volume
931 m³
Parcel 34001B0369/00W000, Flanders · tallest building 10.2 m. Linked by address, not a title deed.
1 establishment unit
D Pharma
Moeskroensesteenweg(Aal) 81, 8511 KortrijkRetail sale of pharmaceutical products
since 2006unit no. 2.150.566.214
1 parcel
Flanders 1 (100%)
Cadastral parcel Region Area Buildings Height / floors
34001B0369/00W000 Flanders 1,099 m² 1 · 124 m² 10.2 m · 3
How the parcels are linked
Good to know
The parcel matches the address exactly.